In Tamoxifen and Fulvestrant-resistant breast cancer, higher levels of secreted and autocrine IL-6 levels are measurable when compared with Tamoxifen-responsive tumors in both the primary tumors and the metastases [94]. Here, IL6 is linked to breast cancer.